Horizon Pharma Inc (HZNP) 25.97 $HZNP
Amgen's Kyprolis Gets FDA Priority Review for Expanded Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 10 mins ago
Amgen's (AMGN) multiple myeloma drug, Kyprolis has been granted priority review in the U.S. for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.
CYTK: 6.78 (-0.32), HZNP: 25.97 (+0.19), AMGN: 159.85 (-4.45), ACOR: 33.28 (-0.63)
Window Dressing Hits Stocks In Final-Hour Sell-Off
at Investor's Business Daily - 2 hrs 35 mins ago
End-of-quarter window dressing caught hold of stocks Tuesday, propelling a sell-off in the final hour of hour of trading. With the first quarter of 2015 proving rocky for investors, portfolio managers may have made their holdings look better by...
AMBA: 75.71 (+1.10), AYI: 168.16 (-4.41), LNKD: 249.86 (-5.33), CBM: 39.63 (+4.04), GRUB: 45.39 (-0.84), HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
3 Small Cap Pharma Stocks Set to Surge Following Q1 Earnings - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Mar 31, 1:33PM CDT
Healthcare has been a great place to invest in over the last few years, but pharmaceuticals have done even better...3 pharma stocks
CRMD: 9.84 (+1.14), IHE: 172.42 (-2.24), IYH: 154.32 (-2.24), HZNP: 25.97 (+0.19), STML: 14.47 (-0.61)
Analysts like Teva and Horizon Pharma
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 11:56AM CDT
HZNP: 25.97 (+0.19), TEVA: 62.30 (-0.22), HPTX: 45.90 (-0.08)
Horizon Pharma Upgraded On 'Game Changer' Acquisition
at Investor's Business Daily - Tue Mar 31, 11:38AM CDT
High-rated specialty-drug stock Horizon Pharma (HZNP) got an upgrade Tuesday in the wake of its deal to acquire an orphan-drug company. Piper Jaffray analyst David Amsellem lifted his rating to overweight from neutral and his price target to 31 from...
HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Ryan & Maniskas, LLP Announces Investigation of Hyperion Therapeutics, Inc.
PR Newswire - Tue Mar 31, 9:40AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Hyperion Therapeutics, Inc. ("Hyperion" or the "Company"
(NASDAQ: HPTX) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Horizon Pharma plc in a transaction valued at approximately $1.1 billion.
HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Horizon Pharma to Buy Hyperion Therapeutics for $1.1B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 9:30AM CDT
Horizon Pharma (HZNP) has announced its intention to acquire Hyperion Therapeutics (HPTX) for around $1.1 billion.
CYTK: 6.78 (-0.32), HZNP: 25.97 (+0.19), AFFX: 12.56 (-0.30), HPTX: 45.90 (-0.08)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of HYPERION THERAPEUTICS INC. of Commencement of an Investigation Concerning the Fairness of the SALE OF THE COMPANY TO HORIZON PHARMA -- HPTX
PR Newswire - Tue Mar 31, 9:25AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Stock Market News for March 31, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 9:10AM CDT
China central bank governor’s indications about additional monetary stimulus and a slew of new deals in the healthcare sector helped benchmarks start the holiday shortened week on a positive note
KMI: 42.06 (-0.01), CTRX: 59.54 (-0.29), RIG: 14.67 (-0.04), UNH: 118.29 (-2.71), EOG: 91.69 (-0.45), HZNP: 25.97 (+0.19), XOM: 85.00 (-0.63), ASPX: 100.27 (-0.09), TEVA: 62.30 (-0.22), CVX: 104.98 (-1.92), HPTX: 45.90 (-0.08)
Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks
at The Street - Tue Mar 31, 8:39AM CDT
Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.
CTRX: 59.54 (-0.29), ADXS: 14.44 (+1.00), UNH: 118.29 (-2.71), HZNP: 25.97 (+0.19), IBB: 343.43 (-7.89), TEVA: 62.30 (-0.22), ASPX: 100.27 (-0.09), NVS: 98.61 (-2.70), HPTX: 45.90 (-0.08)
Hyperion Therapeutics Inc to be acquired by Horizon Pharma plc
M2 - Tue Mar 31, 8:31AM CDT
Horizon Pharma plc (NASDAQ:HZNP) on Monday revealed that it has entered into a definitive agreement with Hyperion Therapeutics Inc (NASDAQ:HPTX).
HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Strength Seen in Horizon Pharma (HZNP): Stock Rises 18.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 7:37AM CDT
Horizon Pharma plc (HZNP) was a big mover last session, as the company saw its shares rise more than 18% on the day.
HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Monday's Rally Was News Oriented - Cramer's Mad Money (3/30/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Mar 31, 6:36AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, March 30. The market rallied big time on Monday and it was led by two streams of money flowing in. First was the news and analysis stream that gave positive...
HRS: 78.76 (+1.13), RH: 99.19 (+0.12), CTRX: 59.54 (-0.29), WGO: 21.26 (+0.20), SWKS: 98.29 (-1.84), FB: 82.21 (-0.98), UNH: 118.29 (-2.71), ASPX: 100.27 (-0.09), RL: 131.50 (-0.77), LULU: 64.02 (-0.81), HPTX: 45.90 (-0.08), NFLX: 416.69 (-5.88), GS: 187.97 (-3.05), HZNP: 25.97 (+0.19), ADI: 63.00 (-1.81), TEVA: 62.30 (-0.22), OA: 76.63 (-0.75), MSFT: 40.65 (-0.31), EXEL: 2.57 (-0.13), PII: 141.10 (-2.29)
Jim Cramer's 'Mad Money' Recap: Good Headlines Make All the Difference
at The Street - Mon Mar 30, 7:06PM CDT
It's nice to see the flow of money has reversed from last week's relentless selloff, Cramer says.
70.87 (-0.27), HRS: 78.76 (+1.13), TSLA: 188.77 (-1.80), RH: 99.19 (+0.12), AMZN: 372.10 (-2.49), CTRX: 59.54 (-0.29), BMRN: 124.62 (-4.51), SWKS: 98.29 (-1.84), NKE: 100.33 (-0.56), ED: 61.00 (+0.21), FCAU: 16.31 (-0.24), WDC: 91.01 (-1.92), SLB: 83.44 (-1.04), LULU: 64.02 (-0.81), NFLX: 416.69 (-5.88), AEP: 56.25 (-0.33), XLS: 24.37 (+0.10), TAC: 9.30 (+0.07), AA: 12.92 (-0.04), NBIX: 39.71 (-1.82), CMI: 138.64 (-1.50), ADI: 63.00 (-1.81), HZNP: 25.97 (+0.19), RCPT: 164.89 (+4.84), TEVA: 62.30 (-0.22)
Robbins Arroyo LLP: Acquisition of Hyperion Therapeutics, Inc. (HPTX) by Horizon Pharma plc (HZNP) May Not Be in Shareholders' Best Interests
PR Newswire - Mon Mar 30, 3:31PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Hyperion Therapeutics, Inc. (NASDAQ: HPTX) by Horizon Pharma plc (NASDAQ: HZNP). On March 30, 2015, the two companies announced the signing of a definitive merger agreement pursuant to which Horizon will acquire Hyperion. Under the terms of the agreement, Hyperion shareholders will receive $46.00 in cash for each share of Hyperion common stock.
HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Stocks Rise Sharply On China Stimulus, Acquisitions
at Investor's Business Daily - Mon Mar 30, 3:28PM CDT
Stocks ended near session highs Monday, buoyed by acquisitions and hopes for stimulus in China. The Dow Jones industrial average rose 1.5%, while the the S&P 500 and Nasdaq each climbed 1.2%. Volume in the stock market today was mixed, down on the...
CTRX: 59.54 (-0.29), CNX: 27.89 (-0.04), UNH: 118.29 (-2.71), HZNP: 25.97 (+0.19), ASPX: 100.27 (-0.09), TEVA: 62.30 (-0.22), HPTX: 45.90 (-0.08)
Stock Markets Soar on Trifecta of Good News
at The Street - Mon Mar 30, 3:08PM CDT
Stocks recapture positive territory for the year on a spate of pharma deals, as well as positive news from the Fed and China.
KMI: 42.06 (-0.01), CTRX: 59.54 (-0.29), UNH: 118.29 (-2.71), ALTR: 42.91 (+0.09), XOM: 85.00 (-0.63), DIS: 104.89 (-1.23), ASPX: 100.27 (-0.09), INTC: 31.27 (-0.19), SLB: 83.44 (-1.04), HPTX: 45.90 (-0.08), NFLX: 416.69 (-5.88), ADI: 63.00 (-1.81), HZNP: 25.97 (+0.19), TEVA: 62.30 (-0.22), CVX: 104.98 (-1.92), MSFT: 40.65 (-0.31), AAPL: 124.43 (-1.94), XLE: 77.58 (-0.46)
HYPERION THERAPEUTICS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Horizon Pharma
Business Wire - Mon Mar 30, 3:05PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. ("Hyperion" (NASDAQ: HPTX) concerning the sale to Horizon Pharma. Under the terms of the agreement, Hyperion shareholders will only receive $46.00 in cash for each share owned, which is virtually no premium over the 52-week high and significantly lower than at least one analyst's estimated value of $52.00 per share.
HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Energy Sector Leads Stock Markets Higher as Rally Rolls On
at The Street - Mon Mar 30, 2:31PM CDT
Stocks recapture positive territory for the year.
KMI: 42.06 (-0.01), CTRX: 59.54 (-0.29), UNH: 118.29 (-2.71), ALTR: 42.91 (+0.09), XOM: 85.00 (-0.63), DIS: 104.89 (-1.23), ASPX: 100.27 (-0.09), INTC: 31.27 (-0.19), SLB: 83.44 (-1.04), HPTX: 45.90 (-0.08), NFLX: 416.69 (-5.88), ADI: 63.00 (-1.81), HZNP: 25.97 (+0.19), TEVA: 62.30 (-0.22), CVX: 104.98 (-1.92), MSFT: 40.65 (-0.31), AAPL: 124.43 (-1.94), XLE: 77.58 (-0.46)
Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Mar 30, 12:43PM CDT
The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion,...
ESRX: 86.77 (+1.37), CTRX: 59.54 (-0.29), ESPR: 92.60 (+0.56), ACAD: 32.59 (-0.76), BMRN: 124.62 (-4.51), ICEL: 16.43 (+0.01), UNH: 118.29 (-2.71), HZNP: 25.97 (+0.19), TEVA: 62.30 (-0.22), ASPX: 100.27 (-0.09), ABBV: 58.54 (+0.30), HPTX: 45.90 (-0.08)
Amgen's Kyprolis Gets FDA Priority Review for Expanded Use - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 10 mins ago
Amgen's (AMGN) multiple myeloma drug, Kyprolis has been granted priority review in the U.S. for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.
CYTK: 6.78 (-0.32), HZNP: 25.97 (+0.19), AMGN: 159.85 (-4.45), ACOR: 33.28 (-0.63)
Window Dressing Hits Stocks In Final-Hour Sell-Off
at Investor's Business Daily - 2 hrs 35 mins ago
End-of-quarter window dressing caught hold of stocks Tuesday, propelling a sell-off in the final hour of hour of trading. With the first quarter of 2015 proving rocky for investors, portfolio managers may have made their holdings look better by...
AMBA: 75.71 (+1.10), AYI: 168.16 (-4.41), LNKD: 249.86 (-5.33), CBM: 39.63 (+4.04), GRUB: 45.39 (-0.84), HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
3 Small Cap Pharma Stocks Set to Surge Following Q1 Earnings - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Mar 31, 1:33PM CDT
Healthcare has been a great place to invest in over the last few years, but pharmaceuticals have done even better...3 pharma stocks
CRMD: 9.84 (+1.14), IHE: 172.42 (-2.24), IYH: 154.32 (-2.24), HZNP: 25.97 (+0.19), STML: 14.47 (-0.61)
Analysts like Teva and Horizon Pharma
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 11:56AM CDT
HZNP: 25.97 (+0.19), TEVA: 62.30 (-0.22), HPTX: 45.90 (-0.08)
Horizon Pharma Upgraded On 'Game Changer' Acquisition
at Investor's Business Daily - Tue Mar 31, 11:38AM CDT
High-rated specialty-drug stock Horizon Pharma (HZNP) got an upgrade Tuesday in the wake of its deal to acquire an orphan-drug company. Piper Jaffray analyst David Amsellem lifted his rating to overweight from neutral and his price target to 31 from...
HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Ryan & Maniskas, LLP Announces Investigation of Hyperion Therapeutics, Inc.
PR Newswire - Tue Mar 31, 9:40AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Hyperion Therapeutics, Inc. ("Hyperion" or the "Company"
(NASDAQ: HPTX) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Horizon Pharma plc in a transaction valued at approximately $1.1 billion. HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Horizon Pharma to Buy Hyperion Therapeutics for $1.1B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 9:30AM CDT
Horizon Pharma (HZNP) has announced its intention to acquire Hyperion Therapeutics (HPTX) for around $1.1 billion.
CYTK: 6.78 (-0.32), HZNP: 25.97 (+0.19), AFFX: 12.56 (-0.30), HPTX: 45.90 (-0.08)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of HYPERION THERAPEUTICS INC. of Commencement of an Investigation Concerning the Fairness of the SALE OF THE COMPANY TO HORIZON PHARMA -- HPTX
PR Newswire - Tue Mar 31, 9:25AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Stock Market News for March 31, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 9:10AM CDT
China central bank governor’s indications about additional monetary stimulus and a slew of new deals in the healthcare sector helped benchmarks start the holiday shortened week on a positive note
KMI: 42.06 (-0.01), CTRX: 59.54 (-0.29), RIG: 14.67 (-0.04), UNH: 118.29 (-2.71), EOG: 91.69 (-0.45), HZNP: 25.97 (+0.19), XOM: 85.00 (-0.63), ASPX: 100.27 (-0.09), TEVA: 62.30 (-0.22), CVX: 104.98 (-1.92), HPTX: 45.90 (-0.08)
Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks
at The Street - Tue Mar 31, 8:39AM CDT
Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.
CTRX: 59.54 (-0.29), ADXS: 14.44 (+1.00), UNH: 118.29 (-2.71), HZNP: 25.97 (+0.19), IBB: 343.43 (-7.89), TEVA: 62.30 (-0.22), ASPX: 100.27 (-0.09), NVS: 98.61 (-2.70), HPTX: 45.90 (-0.08)
Hyperion Therapeutics Inc to be acquired by Horizon Pharma plc
M2 - Tue Mar 31, 8:31AM CDT
Horizon Pharma plc (NASDAQ:HZNP) on Monday revealed that it has entered into a definitive agreement with Hyperion Therapeutics Inc (NASDAQ:HPTX).
HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Strength Seen in Horizon Pharma (HZNP): Stock Rises 18.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 7:37AM CDT
Horizon Pharma plc (HZNP) was a big mover last session, as the company saw its shares rise more than 18% on the day.
HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Monday's Rally Was News Oriented - Cramer's Mad Money (3/30/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Mar 31, 6:36AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, March 30. The market rallied big time on Monday and it was led by two streams of money flowing in. First was the news and analysis stream that gave positive...
HRS: 78.76 (+1.13), RH: 99.19 (+0.12), CTRX: 59.54 (-0.29), WGO: 21.26 (+0.20), SWKS: 98.29 (-1.84), FB: 82.21 (-0.98), UNH: 118.29 (-2.71), ASPX: 100.27 (-0.09), RL: 131.50 (-0.77), LULU: 64.02 (-0.81), HPTX: 45.90 (-0.08), NFLX: 416.69 (-5.88), GS: 187.97 (-3.05), HZNP: 25.97 (+0.19), ADI: 63.00 (-1.81), TEVA: 62.30 (-0.22), OA: 76.63 (-0.75), MSFT: 40.65 (-0.31), EXEL: 2.57 (-0.13), PII: 141.10 (-2.29)
Jim Cramer's 'Mad Money' Recap: Good Headlines Make All the Difference
at The Street - Mon Mar 30, 7:06PM CDT
It's nice to see the flow of money has reversed from last week's relentless selloff, Cramer says.
70.87 (-0.27), HRS: 78.76 (+1.13), TSLA: 188.77 (-1.80), RH: 99.19 (+0.12), AMZN: 372.10 (-2.49), CTRX: 59.54 (-0.29), BMRN: 124.62 (-4.51), SWKS: 98.29 (-1.84), NKE: 100.33 (-0.56), ED: 61.00 (+0.21), FCAU: 16.31 (-0.24), WDC: 91.01 (-1.92), SLB: 83.44 (-1.04), LULU: 64.02 (-0.81), NFLX: 416.69 (-5.88), AEP: 56.25 (-0.33), XLS: 24.37 (+0.10), TAC: 9.30 (+0.07), AA: 12.92 (-0.04), NBIX: 39.71 (-1.82), CMI: 138.64 (-1.50), ADI: 63.00 (-1.81), HZNP: 25.97 (+0.19), RCPT: 164.89 (+4.84), TEVA: 62.30 (-0.22) Robbins Arroyo LLP: Acquisition of Hyperion Therapeutics, Inc. (HPTX) by Horizon Pharma plc (HZNP) May Not Be in Shareholders' Best Interests
PR Newswire - Mon Mar 30, 3:31PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Hyperion Therapeutics, Inc. (NASDAQ: HPTX) by Horizon Pharma plc (NASDAQ: HZNP). On March 30, 2015, the two companies announced the signing of a definitive merger agreement pursuant to which Horizon will acquire Hyperion. Under the terms of the agreement, Hyperion shareholders will receive $46.00 in cash for each share of Hyperion common stock.
HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Stocks Rise Sharply On China Stimulus, Acquisitions
at Investor's Business Daily - Mon Mar 30, 3:28PM CDT
Stocks ended near session highs Monday, buoyed by acquisitions and hopes for stimulus in China. The Dow Jones industrial average rose 1.5%, while the the S&P 500 and Nasdaq each climbed 1.2%. Volume in the stock market today was mixed, down on the...
CTRX: 59.54 (-0.29), CNX: 27.89 (-0.04), UNH: 118.29 (-2.71), HZNP: 25.97 (+0.19), ASPX: 100.27 (-0.09), TEVA: 62.30 (-0.22), HPTX: 45.90 (-0.08)
Stock Markets Soar on Trifecta of Good News
at The Street - Mon Mar 30, 3:08PM CDT
Stocks recapture positive territory for the year on a spate of pharma deals, as well as positive news from the Fed and China.
KMI: 42.06 (-0.01), CTRX: 59.54 (-0.29), UNH: 118.29 (-2.71), ALTR: 42.91 (+0.09), XOM: 85.00 (-0.63), DIS: 104.89 (-1.23), ASPX: 100.27 (-0.09), INTC: 31.27 (-0.19), SLB: 83.44 (-1.04), HPTX: 45.90 (-0.08), NFLX: 416.69 (-5.88), ADI: 63.00 (-1.81), HZNP: 25.97 (+0.19), TEVA: 62.30 (-0.22), CVX: 104.98 (-1.92), MSFT: 40.65 (-0.31), AAPL: 124.43 (-1.94), XLE: 77.58 (-0.46)
HYPERION THERAPEUTICS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Horizon Pharma
Business Wire - Mon Mar 30, 3:05PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. ("Hyperion"
(NASDAQ: HPTX) concerning the sale to Horizon Pharma. Under the terms of the agreement, Hyperion shareholders will only receive $46.00 in cash for each share owned, which is virtually no premium over the 52-week high and significantly lower than at least one analyst's estimated value of $52.00 per share. HZNP: 25.97 (+0.19), HPTX: 45.90 (-0.08)
Energy Sector Leads Stock Markets Higher as Rally Rolls On
at The Street - Mon Mar 30, 2:31PM CDT
Stocks recapture positive territory for the year.
KMI: 42.06 (-0.01), CTRX: 59.54 (-0.29), UNH: 118.29 (-2.71), ALTR: 42.91 (+0.09), XOM: 85.00 (-0.63), DIS: 104.89 (-1.23), ASPX: 100.27 (-0.09), INTC: 31.27 (-0.19), SLB: 83.44 (-1.04), HPTX: 45.90 (-0.08), NFLX: 416.69 (-5.88), ADI: 63.00 (-1.81), HZNP: 25.97 (+0.19), TEVA: 62.30 (-0.22), CVX: 104.98 (-1.92), MSFT: 40.65 (-0.31), AAPL: 124.43 (-1.94), XLE: 77.58 (-0.46)
Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Mar 30, 12:43PM CDT
The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion,...
ESRX: 86.77 (+1.37), CTRX: 59.54 (-0.29), ESPR: 92.60 (+0.56), ACAD: 32.59 (-0.76), BMRN: 124.62 (-4.51), ICEL: 16.43 (+0.01), UNH: 118.29 (-2.71), HZNP: 25.97 (+0.19), TEVA: 62.30 (-0.22), ASPX: 100.27 (-0.09), ABBV: 58.54 (+0.30), HPTX: 45.90 (-0.08)
